No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(-)-3-(4-aminophenyl)-2-methoxypropionic acid |
- |
- |
- |
- |
1件: 97 |
2 |
(r)-3-(1-oxo-propoxy)-4-(n,n,n-trimethyl amonium chloride)-butanoic acid |
Butyric acid |
D05866 |
- |
- |
1件: 97 |
3 |
(s)-(-)-3-(4-aminophenyl)-2-methoxypropionic acid |
- |
- |
- |
- |
1件: 97 |
4 |
(s)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1h-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride |
- |
- |
- |
- |
1件: 97 |
5 |
-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
6 |
0.25 mg rpc1063 |
- |
- |
- |
- |
2件: 96, 97 |
7 |
0.25mg rpc103 |
- |
- |
- |
- |
1件: 97 |
8 |
0.5 mg rpc1063 |
- |
- |
- |
- |
1件: 97 |
9 |
1 mg rpc1063 |
- |
- |
- |
- |
1件: 97 |
10 |
1.0 mg rpc103 |
- |
- |
- |
- |
1件: 97 |
11 |
1.0 mg rpc1063 |
- |
- |
- |
- |
1件: 97 |
12 |
1.remicade |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
13 |
10 mg natura-alpha capsule |
- |
- |
- |
- |
1件: 97 |
14 |
100 mg |
- |
- |
- |
- |
1件: 97 |
15 |
150 mg |
- |
- |
- |
- |
1件: 97 |
16 |
1500mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
17 |
15n2-tofacitinib |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
1件: 97 |
18 |
2 x 10 mg natura-alpha capsules |
- |
- |
- |
- |
1件: 97 |
19 |
2'-fucosyllactose |
- |
- |
- |
- |
2件: 96, 97 |
20 |
2-hydroxybenzoic acid |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
21 |
20 mg |
- |
- |
- |
- |
1件: 97 |
22 |
225mg pf-00547659 |
- |
- |
- |
- |
1件: 97 |
23 |
23-valent polysaccharide pneumococcal vaccine (pneumovax tm) |
- |
- |
- |
- |
2件: 96, 97 |
24 |
250mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
25 |
2l polyethylene glycol/ascorbic acid |
Polyethylene glycol |
D03370 |
- |
- |
1件: 97 |
26 |
331731-18-1 |
- |
- |
- |
- |
2件: 46, 97 |
27 |
40 mg msb11022 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
28 |
42942019 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
29 |
450 mg |
- |
- |
- |
- |
1件: 97 |
30 |
5 asa |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
31 |
5 asa, enemas, suppositories, corticosteroids |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
32 |
5-amino salicylic acid |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
33 |
5-amino salicylic acid (5-asa) |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
34 |
5-amino-2-hydroxybenzoic acid |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
35 |
5-aminosalicyclic acid |
- |
- |
- |
- |
1件: 97 |
36 |
5-aminosalicylate |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
37 |
5-aminosalicylate (pentasa, ferring) |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
38 |
5-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
39 |
5-aminosalicylic acid (5-asa) |
Aminosalicylic acid |
D00162 |
- |
- |
1件: 97 |
40 |
5-aminosalicylic acid(5-asa) and/or prednisone |
Aminosalicylic acid |
D00162 |
- |
- |
1件: 97 |
41 |
5-asa |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
42 |
5-asa (5-aminosalicylate) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
43 |
5-asa mmx |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
44 |
5-htp |
- |
- |
- |
- |
2件: 96, 97 |
45 |
50 mg |
- |
- |
- |
- |
1件: 97 |
46 |
500 mg lx1606 qd |
- |
- |
- |
- |
1件: 97 |
47 |
500 mg lx1606 tid |
- |
- |
- |
- |
1件: 97 |
48 |
500mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
49 |
549-0261/f02-01 |
- |
- |
- |
- |
2件: 96, 97 |
50 |
5asa |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
51 |
6 mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
52 |
6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid |
- |
- |
- |
- |
1件: 97 |
53 |
6-mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 97, 164 |
54 |
6-mp |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
55 |
750mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
56 |
75mg pf-00547659 |
- |
- |
- |
- |
1件: 97 |
57 |
[124i]ib pf 06687234 |
- |
- |
- |
- |
1件: 97 |
58 |
[14c]-rpc1063 solution (0.1 mg/ml) for oral administration |
- |
- |
- |
- |
3件: 13, 96, 97 |
59 |
[18f]fspg |
- |
- |
- |
- |
2件: 96, 97 |
60 |
A multistrain probiotic product (dsf) |
- |
- |
- |
- |
1件: 97 |
61 |
A: 1 dosis |
- |
- |
- |
- |
1件: 97 |
62 |
Ab (antibiotics) |
- |
- |
- |
- |
1件: 97 |
63 |
Abalimumab |
- |
- |
- |
- |
1件: 97 |
64 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
65 |
Abatacept (aba) |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
1件: 97 |
66 |
Abbv-006 |
- |
- |
- |
- |
1件: 97 |
67 |
Abbv-066 |
- |
- |
- |
- |
2件: 96, 97 |
68 |
Abbv-323 dose a |
- |
- |
- |
- |
1件: 97 |
69 |
Abbv-323 dose b |
- |
- |
- |
- |
1件: 97 |
70 |
Abgn-168h |
- |
- |
- |
- |
1件: 97 |
71 |
Abi-m201 |
- |
- |
- |
- |
1件: 97 |
72 |
Abt-494 |
- |
- |
- |
- |
3件: 46, 96, 97 |
73 |
Abx464 |
Abx464 |
- |
- |
- |
3件: 46, 96, 97 |
74 |
Abx464 100mg |
Abx464 |
- |
- |
- |
2件: 46, 97 |
75 |
Abx464 25mg |
Abx464 |
- |
- |
- |
1件: 97 |
76 |
Abx464 50mg |
Abx464 |
- |
- |
- |
2件: 46, 97 |
77 |
Accelerated 1 hour-infusion |
- |
- |
- |
- |
2件: 96, 97 |
78 |
Accelerated 30 minutes-infusion |
- |
- |
- |
- |
2件: 96, 97 |
79 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
80 |
Acetic acid |
Acetic acid |
D00010 |
- |
- |
1件: 97 |
81 |
Active group |
- |
- |
- |
- |
1件: 97 |
82 |
Adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
83 |
Adipose tissue-derived mesenchymal stem cells |
- |
- |
- |
- |
1件: 97 |
84 |
Adipose-cord mesenchymal stromal cells (a-mscs) |
- |
- |
- |
- |
1件: 97 |
85 |
Aeb071 |
- |
- |
- |
- |
1件: 97 |
86 |
Ag011 |
- |
- |
- |
- |
1件: 97 |
87 |
Ag011 - capsules |
- |
- |
- |
- |
1件: 97 |
88 |
Ag011 - enema |
- |
- |
- |
- |
1件: 97 |
89 |
Ajg501 |
- |
- |
- |
- |
1件: 97 |
90 |
Ajg511 |
- |
- |
- |
- |
1件: 97 |
91 |
Ajm300 |
- |
- |
- |
- |
1件: 97 |
92 |
Aldesleukin |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
3件: 49, 65, 97 |
93 |
Alicaforsen |
Alicaforsen |
- |
- |
- |
2件: 96, 97 |
94 |
Alkaline phosphatase |
Alkaline phosphatase |
- |
- |
- |
3件: 46, 97, 172 |
95 |
Allopurinol |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
6件: 6, 46, 57, 66, 96, 97 |
96 |
Aloasc |
- |
- |
- |
- |
1件: 97 |
97 |
Aloe |
Aloe vera leaf |
- |
- |
- |
1件: 97 |
98 |
Aloe barbadensis miller |
Aloe vera leaf |
- |
- |
- |
1件: 97 |
99 |
Alth12-1:4 |
- |
- |
- |
- |
1件: 97 |
100 |
Alth12-2:4 |
- |
- |
- |
- |
1件: 97 |
101 |
Amg 181 |
- |
- |
- |
- |
2件: 96, 97 |
102 |
Amgevita 40mg solution for injection |
- |
- |
- |
- |
2件: 96, 97 |
103 |
Aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
104 |
Amoxicillin |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
6件: 6, 46, 63, 96, 97, 222 |
105 |
Amoxicillin and tetracycline |
Tetracycline |
D00201 |
- |
- |
1件: 97 |
106 |
Amoxicillin, metronidazole and tetracycline |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
1件: 97 |
107 |
And (andrographolide) |
Andrographolide |
- |
- |
- |
1件: 97 |
108 |
Andosan |
- |
- |
- |
- |
2件: 96, 97 |
109 |
Andrographis paniculata |
- |
- |
- |
- |
1件: 97 |
110 |
Andrographis paniculata (ethanol extract) |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
1件: 97 |
111 |
Andrographolide |
Andrographolide |
- |
- |
- |
1件: 97 |
112 |
Anrukinzumab |
Anrukinzumab |
D08857 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
1件: 97 |
113 |
Anti cd3 |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 97 |
114 |
Anti cd3 monoclonal antibody |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 97 |
115 |
Anti tnf therapy including infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
116 |
Anti-cd3 |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
117 |
Anti-cd3 monoclonal antibody |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
118 |
Anti-ip-10 antibody |
- |
- |
- |
- |
1件: 97 |
119 |
Anti-madcam antibody |
- |
- |
- |
- |
2件: 96, 97 |
120 |
Anti-tnf discontinuation: physiological saline solution |
- |
- |
- |
- |
2件: 96, 97 |
121 |
Anti-tnf drug |
- |
- |
- |
- |
2件: 96, 97 |
122 |
Anti-tnf therapy |
- |
- |
- |
- |
3件: 46, 96, 97 |
123 |
Anti-tnf: infliximab (infusion) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
124 |
Anti-tnf:adalimumab (subcutaneus) |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
125 |
Antibiotic cocktail |
- |
- |
- |
- |
1件: 97 |
126 |
Aodg (apigenin-7-o-glucuronide) |
Apigenin |
- |
- |
- |
1件: 97 |
127 |
Apd334 |
- |
- |
- |
- |
4件: 93, 96, 97, 269 |
128 |
Apigenin |
Apigenin |
- |
- |
- |
1件: 97 |
129 |
Apixaban |
Apixaban |
D03213 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 96, 97 |
130 |
Apixaban 2.5 milligram |
Apixaban |
D03213 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 96, 97 |
131 |
Apremilast |
Apremilast |
D08860 |
4件: PDE4A, PDE4B, PDE4C, PDE4D |
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
5件: 46, 50, 56, 97, 271 |
132 |
Apriso 0.375g er cap |
- |
- |
- |
- |
1件: 97 |
133 |
Apriso 375 mg extended-release capsules |
- |
- |
- |
- |
1件: 97 |
134 |
Apvo210 |
- |
- |
- |
- |
1件: 97 |
135 |
Aquamin® |
- |
- |
- |
- |
1件: 97 |
136 |
Asacol |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
137 |
Asacol (mesalamine) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
138 |
Asacol (mesalamine) delayed-release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
139 |
Asacol 400 mg |
- |
- |
- |
- |
1件: 97 |
140 |
Asacol 400 mg (mesalamine) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
141 |
Asacol 400 mg tablet |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
142 |
Asacol 800 mg (mesalamine) |
Mesalazine, Mesalazine |
D00377 |
- |
- |
1件: 97 |
143 |
Asacol 800 mg tablet |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
144 |
Asacol delayed release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
145 |
Asacol delayed-release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
146 |
Asacol tablet |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
147 |
Asacol® |
- |
- |
- |
- |
1件: 97 |
148 |
Asacol® 400 mg |
- |
- |
- |
- |
1件: 97 |
149 |
Ascorbic acid |
Ascorbic acid |
D00018 |
- |
- |
2件: 10, 97 |
150 |
Asp3291 |
- |
- |
- |
- |
1件: 97 |
151 |
Aspergillus oryzae |
Aspergillus oryzae |
- |
- |
- |
1件: 97 |
152 |
Ast-120 |
- |
- |
- |
- |
2件: 96, 97 |
153 |
Atl-2502 |
- |
- |
- |
- |
1件: 97 |
154 |
Avonex |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 13, 97 |
155 |
Avx 470 |
- |
- |
- |
- |
1件: 97 |
156 |
Azafor 50mg |
- |
- |
- |
- |
1件: 97 |
157 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
158 |
Azathioprine (aza) |
Azathioprine |
D00238, D03033 |
- |
- |
2件: 19, 97 |
159 |
Azathioprine (aza) or 6-mercaptopurine (6-mp) |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
160 |
Azathioprine and allopurinol |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 97 |
161 |
Azathioprine or 6-mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
162 |
Azatioprina |
Azathioprine |
D00238, D03033 |
- |
- |
3件: 13, 96, 97 |
163 |
B: 2 dosis |
- |
- |
- |
- |
1件: 97 |
164 |
Bacteriotherapy |
- |
- |
- |
- |
2件: 96, 97 |
165 |
Balsalazide |
Balsalazide |
D02715, D07488 |
- |
- |
1件: 97 |
166 |
Balsalazide disodium |
Balsalazide |
D02715, D07488 |
- |
- |
1件: 97 |
167 |
Baminercept |
Baminercept |
D08866 |
1件: LTB |
3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 53, 97 |
168 |
Bascial prescription plus or minus herbs depend on symptoms |
- |
- |
- |
- |
1件: 97 |
169 |
Basiliximab |
Basiliximab |
D03058 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
6件: 2, 50, 65, 97, 222, 228 |
170 |
Bbt-401-1s, multiple doses |
- |
- |
- |
- |
1件: 97 |
171 |
Bbt-401-1s, single dose |
- |
- |
- |
- |
1件: 97 |
172 |
Beclometasone dipropionate |
Beclomethasone dipropionate |
D00689, D07495 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
173 |
Beclomethasone dipropionate |
Beclomethasone dipropionate |
D00689, D07495 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 97, 98 |
174 |
Beclomethasone diproprionate |
- |
- |
- |
- |
1件: 97 |
175 |
Berberine |
Berberine |
D00092 |
- |
- |
1件: 97 |
176 |
Berberine chloride |
Berberine |
D00092 |
- |
- |
1件: 97 |
177 |
Bertilimumab |
- |
- |
- |
- |
2件: 97, 162 |
178 |
Beta-1,3/1,6-d-glucan |
- |
- |
- |
- |
1件: 97 |
179 |
Bg9418 (interferon beta-1a) |
Human interferon beta |
- |
- |
- |
2件: 13, 97 |
180 |
Bg9924 |
- |
- |
- |
- |
2件: 46, 97 |
181 |
Bi 655130 |
- |
- |
- |
- |
3件: 37, 96, 97 |
182 |
Biap |
- |
- |
- |
- |
2件: 46, 97 |
183 |
Bifidobacterium infantis |
Bifidobacterium longum infantis |
- |
- |
- |
2件: 96, 97 |
184 |
Bifidobacterium infantis 35624 |
Bifidobacterium longum infantis |
- |
- |
- |
2件: 96, 97 |
185 |
Bimekizumab |
Bimekizumab |
D11550 |
2件: IL17A, IL17F |
5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
3件: 46, 97, 271 |
186 |
Bio-enhanced curcumin soft gelatin capsule |
Curcumin |
- |
- |
- |
1件: 97 |
187 |
Biologically active human fecal microbiota |
- |
- |
- |
- |
1件: 97 |
188 |
Biopsies |
- |
- |
- |
- |
1件: 97 |
189 |
Biosimilar |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
190 |
Biosimilar infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
191 |
Bitter candytuft fresh plant extract |
- |
- |
- |
- |
1件: 97 |
192 |
Bitterschleifenblume-ganzpflanze 1,5ml/10ml |
- |
- |
- |
- |
1件: 97 |
193 |
Bl-7040 |
- |
- |
- |
- |
1件: 97 |
194 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
195 |
Blood samples |
- |
- |
- |
- |
8件: 13, 41, 46, 51, 61, 97, 227, 271 |
196 |
Bms-188667 |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
6件: 46, 49, 65, 96, 97, 271 |
197 |
Bms-986165 |
- |
- |
- |
- |
3件: 49, 96, 97 |
198 |
Bms-986166 |
- |
- |
- |
- |
1件: 97 |
199 |
Bms-986184 |
- |
- |
- |
- |
1件: 97 |
200 |
Boulardii |
- |
- |
- |
- |
2件: 96, 97 |
201 |
Bovine intestinal alkaline phosphatase (biap) |
Alkaline phosphatase |
- |
- |
- |
1件: 97 |
202 |
Bovine-calf alkaline phosphatase (biap) |
Alkaline phosphatase |
- |
- |
- |
1件: 97 |
203 |
Bovine-calf alkaline phosphatase biap |
Alkaline phosphatase |
- |
- |
- |
1件: 97 |
204 |
Brazikumab |
- |
- |
- |
- |
2件: 96, 97 |
205 |
Bt-11 (1000 mg) |
- |
- |
- |
- |
1件: 97 |
206 |
Bt-11 (500 mg) |
- |
- |
- |
- |
1件: 97 |
207 |
Bt-11 active |
- |
- |
- |
- |
2件: 96, 97 |
208 |
Budenofalk 2mg rectal foam |
- |
- |
- |
- |
1件: 97 |
209 |
Budenofalk 3mg |
- |
- |
- |
- |
2件: 93, 97 |
210 |
Budenofalk rectal foam |
- |
- |
- |
- |
1件: 97 |
211 |
Budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 |
212 |
Budesonide (6 mg) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
213 |
Budesonide (9 mg) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
214 |
Budesonide 6 mg capsules, hard (bux-pvii prototype) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
215 |
Budesonide 9 mg capsules, hard (bux-pv) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
216 |
Budesonide 9 mg capsules, hard (bux-pvii prototype) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
217 |
Budesonide mmx 6 mg tablet |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
218 |
Budesonide mmx® |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
219 |
Budesonide mmx® 6 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
220 |
Budesonide mmx® 9 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
221 |
Budesonide-mmx |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
222 |
Budesonide-mmx® |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
223 |
Budesonide-mmx® 6 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
224 |
Budesonide-mmx® 9 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
225 |
Budesonide-mmx™ |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
226 |
Butanoic acid |
Butyric acid |
D05866 |
- |
- |
3件: 34, 51, 97 |
227 |
Caffeine |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 2, 6, 46, 78, 96, 97 |
228 |
Calcitonin nasal spray (salmon) |
- |
- |
- |
- |
2件: 96, 97 |
229 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
230 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
231 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
232 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
233 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
7件: 6, 46, 85, 86, 96, 97, 298 |
234 |
Carbon dioxide |
Carbon dioxide |
D00004 |
- |
- |
1件: 97 |
235 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
8件: 5, 13, 58, 96, 97, 265, 298, 316 |
236 |
Carrageenan |
- |
- |
- |
- |
1件: 97 |
237 |
Carvi extractum fluidum |
- |
- |
- |
- |
1件: 97 |
238 |
Casein |
Casein |
- |
- |
- |
1件: 97 |
239 |
Casein glycomacropeptide (cgmp) |
Casein |
- |
- |
- |
1件: 97 |
240 |
Cat-354 |
- |
- |
- |
- |
1件: 97 |
241 |
Catridecacog |
Catridecacog |
D10532 |
- |
- |
2件: 97, 288 |
242 |
Cb-01-02 |
- |
- |
- |
- |
1件: 97 |
243 |
Cb-01-05-mmx |
- |
- |
- |
- |
1件: 97 |
244 |
Ceftriaxone |
Ceftriaxone |
D00924, D07659 |
- |
- |
3件: 2, 6, 97 |
245 |
Cefuroxime |
Cefuroxime |
D00262, D00914, D00915, D03431 |
- |
- |
1件: 97 |
246 |
Certolizumab pegol |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 37, 46, 96, 97, 226, 271 |
247 |
Cgmp |
Cyclic gmp |
- |
- |
- |
1件: 97 |
248 |
Cgmp protein |
Cyclic gmp |
- |
- |
- |
1件: 97 |
249 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
250 |
Chlorogenic acid |
Chlorogenic acid |
- |
- |
- |
1件: 97 |
251 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
252 |
Ciclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
13件: 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 |
253 |
Cimzia |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
254 |
Ciprofloxacin |
Ciprofloxacin |
D00186, D02216 |
- |
- |
5件: 2, 60, 96, 97, 299 |
255 |
Cla (chlorogenic acid) |
Chlorogenic acid |
- |
- |
- |
1件: 97 |
256 |
Clarithromycin |
Clarithromycin |
D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
257 |
Clipper |
- |
- |
- |
- |
1件: 97 |
258 |
Clotrimazole |
Clotrimazole |
D00282 |
- |
- |
1件: 97 |
259 |
Cnto148 |
- |
- |
- |
- |
2件: 46, 97 |
260 |
Coamoxiclav |
- |
- |
- |
- |
1件: 97 |
261 |
Cobitolimod |
Cobitolimod |
- |
- |
- |
1件: 97 |
262 |
Coffee coal |
- |
- |
- |
- |
1件: 97 |
263 |
Colal-pred |
- |
- |
- |
- |
1件: 97 |
264 |
Colal-pred® |
- |
- |
- |
- |
1件: 97 |
265 |
Coltect |
- |
- |
- |
- |
1件: 97 |
266 |
Combination oral budesonide and rectal hydrocortisone |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
267 |
Corticosteroid |
- |
- |
- |
- |
10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
268 |
Corticosteroids |
- |
- |
- |
- |
9件: 41, 46, 49, 64, 97, 164, 220, 296, 300 |
269 |
Corticosteroids only |
- |
- |
- |
- |
1件: 97 |
270 |
Corticosteroids then mesalamine |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
271 |
Cortimentmmx 9 mg |
- |
- |
- |
- |
1件: 97 |
272 |
Cosmofer |
- |
- |
- |
- |
2件: 96, 97 |
273 |
Cosmofer 50mg/ml solution for infusion or injection |
- |
- |
- |
- |
2件: 96, 97 |
274 |
Cotrimoxazole |
- |
- |
- |
- |
2件: 85, 97 |
275 |
Cp- 690 550 |
- |
- |
- |
- |
1件: 97 |
276 |
Cp-690,500 5 mg |
- |
- |
- |
- |
1件: 97 |
277 |
Cp-690,550 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
278 |
Cp-690,550 10 mg |
- |
- |
- |
- |
1件: 97 |
279 |
Cp-690,550-10 |
- |
- |
- |
- |
3件: 46, 96, 97 |
280 |
Cp690,550 |
- |
- |
- |
- |
2件: 46, 97 |
281 |
Cs (corticosteroids) only |
- |
- |
- |
- |
1件: 97 |
282 |
Ct-p13 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
283 |
Curcumin |
Curcumin |
- |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
284 |
Cyclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
16件: 14, 38, 39, 49, 53, 56, 60, 62, 63, 97, 113, 164, 222, 223, 274, 326 |
285 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
286 |
Cyclosporine (usan) |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 97 |
287 |
Cyclosporine vs infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
288 |
Cycol |
- |
- |
- |
- |
1件: 97 |
289 |
Cycol™ |
- |
- |
- |
- |
1件: 97 |
290 |
D-proline |
Proline |
D00035 |
- |
- |
1件: 97 |
291 |
Daclizumab |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
7件: 13, 56, 60, 65, 97, 283, 284 |
292 |
Dacortin |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 46, 97 |
293 |
Dand (14-deoxyandrographolide) |
- |
- |
- |
- |
1件: 97 |
294 |
Ddand (14-deoxy-11,12-didehydroandrographolide) |
- |
- |
- |
- |
1件: 97 |
295 |
Decortin |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
5件: 46, 96, 97, 113, 145 |
296 |
Decortin h 1 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
297 |
Decortin h 10mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
298 |
Decortin h 20mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
299 |
Decortin h 50 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
300 |
Decortin h 5mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
301 |
Dekristol |
- |
- |
- |
- |
2件: 13, 97 |
302 |
Deligoparin |
- |
- |
- |
- |
1件: 97 |
303 |
Delmitide acetate |
Acetate |
- |
- |
- |
1件: 97 |
304 |
Deltacortene |
- |
- |
- |
- |
1件: 97 |
305 |
Dersalazine |
Dersalazine |
- |
- |
- |
1件: 97 |
306 |
Dersalazine sodium |
Dersalazine |
- |
- |
- |
1件: 97 |
307 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
308 |
Dexamethasone 21-phosphate |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
309 |
Dextran |
Dextran |
D00060 |
- |
- |
5件: 2, 62, 79, 96, 97 |
310 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
311 |
Dims0150 |
- |
- |
- |
- |
1件: 97 |
312 |
Doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
313 |
E. coli nissle |
- |
- |
- |
- |
1件: 97 |
314 |
Ecologic 825 |
- |
- |
- |
- |
1件: 97 |
315 |
Egf enema |
- |
- |
- |
- |
1件: 97 |
316 |
Eicosapentaenoic acid |
Icosapent |
D08061 |
- |
- |
5件: 49, 96, 97, 296, 297 |
317 |
Emea/h/c/000481 |
- |
- |
- |
- |
1件: 97 |
318 |
Encapsulated faecal microbiota |
- |
- |
- |
- |
1件: 97 |
319 |
Encapsulated faecal microbiota filtrate |
- |
- |
- |
- |
1件: 97 |
320 |
Entecavir |
Entecavir |
D04008, D07896 |
- |
- |
5件: 46, 56, 96, 97, 271 |
321 |
Entocort ec® 3 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
322 |
Entocort® cr |
- |
- |
- |
- |
1件: 97 |
323 |
Entyvio |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
324 |
Entyvio 300mg |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
1件: 97 |
325 |
Epaxal berna (virosomal hepatitis a vaccine) |
Hepatitis a vaccine |
- |
- |
- |
2件: 96, 97 |
326 |
Epidermal growth factor |
- |
- |
- |
- |
1件: 97 |
327 |
Epidermal growth factor enema |
- |
- |
- |
- |
1件: 97 |
328 |
Ergocalciferol |
Ergocalciferol |
D00187 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
5件: 46, 84, 96, 97, 299 |
329 |
Ethanol |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
3件: 97, 279, 280 |
330 |
Etrasimod |
Etrasimod |
D10930 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 97 |
331 |
Etrolizumab |
Etrolizumab |
D09901 |
1件: ITGB7 |
11件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer |
2件: 96, 97 |
332 |
Etrozulimab |
- |
- |
- |
- |
1件: 97 |
333 |
Eubacterial spores, purified suspension, encapsulated |
- |
- |
- |
- |
1件: 97 |
334 |
Exposure to golimumab |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
335 |
Faecal microbiota transplantation |
- |
- |
- |
- |
2件: 96, 97 |
336 |
Fe 999301 |
- |
- |
- |
- |
2件: 96, 97 |
337 |
Fecal microbial transplant |
- |
- |
- |
- |
2件: 96, 97 |
338 |
Fecal microbial transplantation |
- |
- |
- |
- |
2件: 96, 97 |
339 |
Fecal microbiota |
- |
- |
- |
- |
2件: 13, 97 |
340 |
Fecal microbiota enema |
- |
- |
- |
- |
1件: 97 |
341 |
Fecal microbiota transplant |
- |
- |
- |
- |
2件: 96, 97 |
342 |
Fecal microbiota transplantation |
- |
- |
- |
- |
5件: 2, 66, 94, 96, 97 |
343 |
Fecal microbiota transplantation (fmt) |
- |
- |
- |
- |
2件: 96, 97 |
344 |
Fecal microbiota transplantation (fmt), openbiome |
- |
- |
- |
- |
1件: 97 |
345 |
Ferric carboxymaltose |
Ferric carboxymaltose |
D08920 |
- |
- |
4件: 86, 96, 97, 299 |
346 |
Ferrous sulphate |
- |
- |
- |
- |
2件: 96, 97 |
347 |
Filgotinib |
Filgotinib |
D10871 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
6件: 46, 53, 96, 97, 222, 271 |
348 |
Fitc-adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
349 |
Flagyl |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
2件: 96, 97 |
350 |
Flaxseed lignan-enriched complex (flc) |
- |
- |
- |
- |
1件: 97 |
351 |
Flixabi |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
352 |
Fluorescein |
Fluorescein |
D01261, D02024 |
- |
- |
2件: 19, 97 |
353 |
Flupentixol |
Flupentixol |
D01044 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 97 |
354 |
Fmt infusions |
- |
- |
- |
- |
1件: 97 |
355 |
Fosfomycin |
Fosfomycin |
D00925, D02187, D02188, D04253 |
- |
- |
2件: 96, 97 |
356 |
Fp-110 |
- |
- |
- |
- |
1件: 97 |
357 |
Fp-cya-050 |
- |
- |
- |
- |
1件: 97 |
358 |
Fp-cya-053 |
- |
- |
- |
- |
1件: 97 |
359 |
Freeze-dried black raspberry powder |
Raspberry |
- |
- |
- |
1件: 97 |
360 |
G321605 |
- |
- |
- |
- |
3件: 85, 96, 97 |
361 |
Ganciclovir |
Ganciclovir |
D00333, D04301 |
- |
- |
3件: 28, 60, 97 |
362 |
Gastro-resistant phosphatidylcholine granules |
- |
- |
- |
- |
1件: 97 |
363 |
Gb004 |
- |
- |
- |
- |
1件: 97 |
364 |
Ged-0301 |
- |
- |
- |
- |
2件: 96, 97 |
365 |
Ged-0507-34-levo |
- |
- |
- |
- |
1件: 97 |
366 |
Ged-0507-34-levo 160 mg |
- |
- |
- |
- |
1件: 97 |
367 |
Ged-0507-34-levo 80 mg |
- |
- |
- |
- |
1件: 97 |
368 |
Ged0507 |
- |
- |
- |
- |
1件: 97 |
369 |
Gelatin |
Gelatin |
D00115, D06892 |
- |
- |
4件: 47, 78, 97, 269 |
370 |
Gi-270384 |
- |
- |
- |
- |
1件: 97 |
371 |
Glpg0974 |
Glpg0974 |
- |
- |
- |
1件: 97 |
372 |
Glpg1205 |
Glpg1205 |
- |
- |
- |
3件: 85, 96, 97 |
373 |
Glutamine |
L-glutamine |
D00015 |
- |
- |
6件: 87, 96, 97, 113, 245, 299 |
374 |
Glycyrrhiza |
Glycyrrhiza glabra |
- |
- |
- |
1件: 97 |
375 |
Glycyrrhiza glabra |
Glycyrrhiza glabra |
- |
- |
- |
1件: 97 |
376 |
Glycyrrhiza glabra root |
Glycyrrhiza glabra |
- |
- |
- |
1件: 97 |
377 |
Golimumab |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
5件: 46, 84, 96, 97, 271 |
378 |
Golimumab (glm) |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
379 |
Golimumab (optimization) |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
380 |
Golimumab 1 mg per kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
381 |
Golimumab 100 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 97 |
382 |
Golimumab 2 mg per kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
383 |
Golimumab 200 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
384 |
Golimumab 4 mg per kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
385 |
Golimumab 400 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
386 |
Golimumab 50 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 97 |
387 |
Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
388 |
Golimumab dose 1 |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
389 |
Golimumab dose 2 |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
390 |
Golimumab prefilled syringe |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
391 |
Golimumab treatment optimization. |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
392 |
Gralise |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
2件: 97, 226 |
393 |
Granulated mesalamine |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
394 |
Grapefruit |
Grapefruit |
- |
- |
- |
5件: 6, 46, 50, 83, 97 |
395 |
Group 1- control diet |
- |
- |
- |
- |
1件: 97 |
396 |
Group 2- ucd diet |
- |
- |
- |
- |
1件: 97 |
397 |
Gs-4875 |
- |
- |
- |
- |
1件: 97 |
398 |
Gs-5745 |
- |
- |
- |
- |
2件: 46, 97 |
399 |
Gs-5745 iv |
- |
- |
- |
- |
1件: 97 |
400 |
Gs-5745 sc |
- |
- |
- |
- |
1件: 97 |
401 |
Gs-6034 |
- |
- |
- |
- |
3件: 46, 96, 97 |
402 |
Gsk1399686 |
- |
- |
- |
- |
1件: 97 |
403 |
Gsk1605786 |
- |
- |
- |
- |
2件: 96, 97 |
404 |
Gsk1605786a |
- |
- |
- |
- |
2件: 96, 97 |
405 |
Gsk2586184 400mg |
- |
- |
- |
- |
1件: 97 |
406 |
Gsk2831781 |
- |
- |
- |
- |
1件: 97 |
407 |
Gsk2982772 |
- |
- |
- |
- |
2件: 46, 97 |
408 |
Gsk2982772a, where a denotes the free base |
- |
- |
- |
- |
2件: 46, 97 |
409 |
Guaiazulene |
Guaiazulen |
- |
- |
- |
1件: 97 |
410 |
Guselkumab |
Guselkumab |
D10438 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
3件: 37, 96, 97 |
411 |
Guselkumab dose 1 |
Guselkumab |
D10438 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
1件: 97 |
412 |
Guselkumab dose 2 |
Guselkumab |
D10438 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
1件: 97 |
413 |
Gwp42003 |
- |
- |
- |
- |
1件: 97 |
414 |
He3286 |
He3286 |
- |
- |
- |
2件: 46, 97 |
415 |
Hemay007 |
- |
- |
- |
- |
1件: 97 |
416 |
Hepatitis a vaccine |
Hepatitis a vaccine |
- |
- |
- |
3件: 46, 96, 97 |
417 |
Herbal treatment (sa100) |
- |
- |
- |
- |
1件: 97 |
418 |
Hextend |
Hydroxyethyl starch |
D03335 |
- |
- |
2件: 96, 97 |
419 |
Hgd40 |
- |
- |
- |
- |
1件: 97 |
420 |
Hgs1025 |
- |
- |
- |
- |
1件: 97 |
421 |
High dose |
- |
- |
- |
- |
1件: 97 |
422 |
Hmpl-004 |
- |
- |
- |
- |
1件: 97 |
423 |
Hmpl-004 tablet |
- |
- |
- |
- |
1件: 97 |
424 |
Hmpl004-6599 |
- |
- |
- |
- |
2件: 96, 97 |
425 |
Hum291 |
- |
- |
- |
- |
2件: 96, 97 |
426 |
Human anti-tnf-alpha monoclonal antibody |
- |
- |
- |
- |
2件: 46, 97 |
427 |
Humira |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 46, 84, 96, 97, 269, 271 |
428 |
Humira 40 mg solution for injection in pre-filled syringe |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
429 |
Humira 40 mg solution for injection in pre-filled syringes |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
430 |
Humira 40 mg/0.8 ml solution for injection for paediatric use |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
431 |
Humira 40mg solution for injection |
- |
- |
- |
- |
2件: 96, 97 |
432 |
Humira® |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
433 |
Hyaluronate |
Hyaluronic acid |
D08043 |
- |
- |
2件: 53, 97 |
434 |
Hydrocortisone |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
435 |
Hydrocortisone sodium succinate |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
436 |
Hydrogen |
Hydrogen |
- |
- |
- |
5件: 5, 6, 17, 97, 226 |
437 |
Hydroxide |
Hydroxide ion |
- |
- |
- |
4件: 46, 96, 97, 284 |
438 |
Ibd98-m |
- |
- |
- |
- |
1件: 97 |
439 |
Ibd98-m delayed-release capsules |
- |
- |
- |
- |
1件: 97 |
440 |
Iberogast n |
- |
- |
- |
- |
1件: 97 |
441 |
Im90838 |
- |
- |
- |
- |
1件: 97 |
442 |
Impact |
Topramezone |
- |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
443 |
Imu-838 |
- |
- |
- |
- |
1件: 97 |
444 |
Imuran |
Azathioprine |
D00238, D03033 |
- |
- |
2件: 96, 97 |
445 |
Imurek 25mg filmtabletten |
- |
- |
- |
- |
1件: 97 |
446 |
Imurek 50mg filmtabletten |
- |
- |
- |
- |
1件: 97 |
447 |
Imurel |
- |
- |
- |
- |
2件: 96, 97 |
448 |
Inflectra |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
449 |
Infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
22件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
450 |
Infliximab (ifx) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
451 |
Infliximab 10 mg/kg |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
452 |
Infliximab 5 mg/kg |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
453 |
Infliximab [infliximab biosimilar 3] |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 37, 46, 96, 97 |
454 |
Infliximab and adalimumab |
Adalimumab, Infliximab |
D02597, D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
455 |
Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab |
Ustekinumab, Vedolizumab |
D08083, D09214 |
5件: IL12A, IL12B, IL23A, ITGA4, ITGB7 |
39件: African trypanosomiasis, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy (ARVC), C-type lectin receptor signaling pathway, Cell adhesion molecules (CAMs), Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Malaria, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
2件: 96, 97 |
456 |
Infliximab, adalimumab, certolizumab pegol |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
457 |
Innovator infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
458 |
Inositol |
Inositol |
D08079 |
- |
- |
2件: 96, 97 |
459 |
Interferon beta |
Human interferon beta |
- |
- |
- |
6件: 13, 14, 20, 26, 96, 97 |
460 |
Interferon beta-1a |
Human interferon beta |
- |
- |
- |
5件: 13, 14, 26, 96, 97 |
461 |
Interferon-beta |
Human interferon beta |
- |
- |
- |
2件: 13, 97 |
462 |
Interferon-beta-1a |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 13, 97 |
463 |
Interferon-beta-1a, 44 microgram |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 97 |
464 |
Interferon-beta-1a, 66 microgram |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 97 |
465 |
Interleukin 2 |
Human interleukin-2 |
- |
- |
- |
9件: 46, 49, 51, 56, 63, 95, 96, 97, 271 |
466 |
Interleukin-2 |
Human interleukin-2 |
- |
- |
- |
6件: 2, 35, 49, 55, 65, 97 |
467 |
Interleukin-2 (aldesleukin). |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
1件: 97 |
468 |
Iron |
Iron |
- |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
469 |
Iron sucrose |
Sucrose |
D00025 |
- |
- |
3件: 62, 96, 97 |
470 |
Iron sulphate |
Iron |
- |
- |
- |
2件: 96, 97 |
471 |
Iron sulphate 200mg coated tablets |
Iron |
- |
- |
- |
2件: 96, 97 |
472 |
Iron supplement 300-600 mg/day |
Iron |
- |
- |
- |
2件: 96, 97 |
473 |
Iron(iii)- hydroxide dextran complex |
Dextran |
D00060 |
- |
- |
2件: 96, 97 |
474 |
Itacitinib |
Itacitinib |
D10944 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
4件: 46, 60, 97, 228 |
475 |
Jenapharm |
Acetylcysteine |
D00221 |
- |
- |
2件: 96, 97 |
476 |
Jnj-54781532 150 mg once daily |
- |
- |
- |
- |
1件: 97 |
477 |
Jnj-54781532 25 mg once daily |
- |
- |
- |
- |
1件: 97 |
478 |
Jnj-54781532 75 mg once daily |
- |
- |
- |
- |
1件: 97 |
479 |
Jnj-54781532 75 mg twice daily |
- |
- |
- |
- |
1件: 97 |
480 |
K(d)pt |
- |
- |
- |
- |
1件: 97 |
481 |
Kamillenblüten 3ml/10ml |
- |
- |
- |
- |
1件: 97 |
482 |
Kappaproct |
- |
- |
- |
- |
1件: 97 |
483 |
Kdpt |
- |
- |
- |
- |
1件: 97 |
484 |
Khk4083 |
- |
- |
- |
- |
1件: 97 |
485 |
Kremezin |
- |
- |
- |
- |
2件: 96, 97 |
486 |
Kremezin®, spherical adsorptive carbon |
Activated charcoal |
D03251 |
- |
- |
2件: 96, 97 |
487 |
Krp203a |
- |
- |
- |
- |
1件: 97 |
488 |
Kyo-dophilus |
- |
- |
- |
- |
1件: 97 |
489 |
Kümmel 2ml/10ml |
- |
- |
- |
- |
1件: 97 |
490 |
L-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
6件: 13, 96, 97, 265, 298, 316 |
491 |
L-lysyl-d-prolyl-l-threonine acetate |
Acetate |
- |
- |
- |
1件: 97 |
492 |
L-threonine |
L-threonine |
D00041 |
- |
- |
1件: 97 |
493 |
Lactated ringers |
- |
- |
- |
- |
2件: 96, 97 |
494 |
Lactobacillus casei dg |
- |
- |
- |
- |
1件: 97 |
495 |
Lactobacillus gg |
- |
- |
- |
- |
1件: 97 |
496 |
Lactobacillus reuteri |
Lactobacillus reuteri |
- |
- |
- |
2件: 97, 299 |
497 |
Lactobacillus rhamnosus gg atcc 53103 |
- |
- |
- |
- |
1件: 97 |
498 |
Lactobacillus salivarius ucc118 |
- |
- |
- |
- |
2件: 96, 97 |
499 |
Lactobacilus acidophilus & bifidobacterium animalis/lactis |
- |
- |
- |
- |
1件: 97 |
500 |
Lactose |
Lactose |
D00046, D03226 |
- |
- |
6件: 2, 6, 13, 97, 228, 310 |
501 |
Lactose in water |
Lactose |
D00046, D03226 |
- |
- |
1件: 97 |
502 |
Lc51-0255 |
- |
- |
- |
- |
1件: 97 |
503 |
Levocarnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
3件: 3, 53, 97 |
504 |
Levocarnitine propyl hydrochloride |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
1件: 97 |
505 |
Linaclotide |
Linaclotide |
D09355 |
1件: GUCY2C |
2件: Metabolic pathways, Purine metabolism |
1件: 97 |
506 |
Lixacol |
- |
- |
- |
- |
1件: 97 |
507 |
Loperamide |
Loperamide |
D00729, D07113, D08144 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 13, 97 |
508 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
509 |
Low dose |
- |
- |
- |
- |
1件: 97 |
510 |
Low dose naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 96, 97 |
511 |
Low fodmap |
- |
- |
- |
- |
1件: 97 |
512 |
Lt-02 |
- |
- |
- |
- |
1件: 97 |
513 |
Lt-02 (modified-release pc pellets) |
- |
- |
- |
- |
1件: 97 |
514 |
Lumbar puncture |
- |
- |
- |
- |
3件: 13, 96, 97 |
515 |
Lx1606 |
- |
- |
- |
- |
1件: 97 |
516 |
Ly3074828 |
- |
- |
- |
- |
1件: 97 |
517 |
Lyc-30937 |
- |
- |
- |
- |
1件: 97 |
518 |
Lyc-30937-ec |
- |
- |
- |
- |
1件: 97 |
519 |
Lys006 |
- |
- |
- |
- |
1件: 97 |
520 |
Lysine |
L-lysine |
D02304 |
- |
- |
4件: 13, 97, 228, 299 |
521 |
Lysine-d-proline-threonine |
Proline |
D00035 |
- |
- |
1件: 97 |
522 |
Magnesium |
Magnesium |
- |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
523 |
Magnesium citrate |
Magnesium citrate |
D03265 |
- |
- |
1件: 97 |
524 |
Maltodextrin |
Maltodextrin |
D02329 |
- |
- |
4件: 6, 13, 96, 97 |
525 |
Maltose |
Maltose |
D00044 |
- |
- |
2件: 96, 97 |
526 |
Mare´s milk |
- |
- |
- |
- |
2件: 96, 97 |
527 |
Matricaria flower |
Chamomile |
D09212 |
- |
- |
1件: 97 |
528 |
Matricaria recutita l. flos |
- |
- |
- |
- |
1件: 97 |
529 |
Maximal oral 5asa |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
530 |
Md-0901 |
- |
- |
- |
- |
1件: 97 |
531 |
Mdx-1100 |
- |
- |
- |
- |
2件: 46, 97 |
532 |
Mdx-1100 (anti-cxcl10 human monoclonal antibody) |
- |
- |
- |
- |
1件: 97 |
533 |
Medi7183 high dose |
- |
- |
- |
- |
1件: 97 |
534 |
Medi7183 low dose |
- |
- |
- |
- |
1件: 97 |
535 |
Medi7183 medium dose |
- |
- |
- |
- |
1件: 97 |
536 |
Melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
537 |
Melissae folii dry aqueous extract |
- |
- |
- |
- |
1件: 97 |
538 |
Melissenblätter 15ml/10ml |
- |
- |
- |
- |
1件: 97 |
539 |
Melitracen |
Melitracen |
D08171 |
- |
- |
1件: 97 |
540 |
Mentha × piperita l. folium |
- |
- |
- |
- |
1件: 97 |
541 |
Mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
3件: 96, 97, 164 |
542 |
Mercaptopurine (puri-nethol) |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 97 |
543 |
Mesalamin |
- |
- |
- |
- |
1件: 97 |
544 |
Mesalamine |
Mesalazine |
D00377 |
- |
- |
3件: 96, 97, 164 |
545 |
Mesalamine delayed release tablets 400mg |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
546 |
Mesalamine enema |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
547 |
Mesalamine granules |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
548 |
Mesalamine once-daily |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
549 |
Mesalamine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
550 |
Mesalamine twice-daily |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
551 |
Mesalamine, 5-asa |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
552 |
Mesalazine |
Mesalazine |
D00377 |
- |
- |
3件: 46, 96, 97 |
553 |
Mesalazine (3,600 mg) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
554 |
Mesalazine - tid 1000 mg |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
555 |
Mesalazine - tid 2x 500 mg |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
556 |
Mesalazine 1000 mg gastro-resistant tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
557 |
Mesalazine 250mg |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
558 |
Mesalazine 250mg tablet and nitazoxanide 500mg oral tablet |
Nitazoxanide |
D02486 |
- |
- |
1件: 97 |
559 |
Mesalazine 4g enema |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
560 |
Mesalazine 500 mg gastro-resistant tablets (salofalk® 500 mg) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
561 |
Mesalazine enema |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
562 |
Mesalazine tablet |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
563 |
Mesalazine with hydrocortisone sodium succinate |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
564 |
Mesalazinum |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
565 |
Mesenchymal cells |
- |
- |
- |
- |
1件: 97 |
566 |
Mesenchymal stromal cells |
- |
- |
- |
- |
6件: 36, 51, 96, 97, 274, 284 |
567 |
Met-2 |
- |
- |
- |
- |
1件: 97 |
568 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
569 |
Methotrexate bellon |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
1件: 97 |
570 |
Methotrexate bellon 25mg/ml |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
1件: 97 |
571 |
Methylene blue |
Methylene blue |
D02312, D10537 |
- |
- |
1件: 97 |
572 |
Methylene blue 25mg tablets |
Methylene blue |
D02312, D10537 |
- |
- |
1件: 97 |
573 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
574 |
Metronidazole |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
8件: 46, 51, 63, 94, 95, 96, 97, 291 |
575 |
Metronidazole capsule 50 mg |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
1件: 97 |
576 |
Mezavant |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
577 |
Mezavant 1200 mg magensaftresistente retardtabletten |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
578 |
Mezavant xl |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
579 |
Mezavant xl 1200 mg gastro-resistant, prolonged release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
580 |
Mezavant xl 1200 mg gastro-resistant, prolonged release tablets. |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
581 |
Mezavant xl gastro-resistant, prolonged release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
582 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
583 |
Mirikizumab |
Mirikizumab |
D11123 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
2件: 96, 97 |
584 |
Mk-8259 |
- |
- |
- |
- |
1件: 97 |
585 |
Mln0002 |
- |
- |
- |
- |
2件: 96, 97 |
586 |
Mln0002 (vedolizumab) |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
587 |
Mln002 |
- |
- |
- |
- |
2件: 96, 97 |
588 |
Mmx mesalamine |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
589 |
Mmx mesalamine/mesalazine |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
590 |
Mmx mesalamine/mesalazine (high dose) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
591 |
Mmx mesalamine/mesalazine (low dose) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
592 |
Modified gegen qinlian decoction |
- |
- |
- |
- |
1件: 97 |
593 |
Modified-release phosphatidylcholine |
- |
- |
- |
- |
1件: 97 |
594 |
Mongersen |
Mongersen |
D10956 |
1件: SMAD7 |
2件: Hippo signaling pathway, TGF-beta signaling pathway |
2件: 96, 97 |
595 |
Monoclonal antibody anti-igg1 |
- |
- |
- |
- |
3件: 37, 96, 97 |
596 |
Mtx 12.5 |
- |
- |
- |
- |
1件: 97 |
597 |
Mtx 25 |
- |
- |
- |
- |
1件: 97 |
598 |
Multiple dose- group b |
- |
- |
- |
- |
1件: 97 |
599 |
Multiple dose-group b |
- |
- |
- |
- |
1件: 97 |
600 |
Multistem high dose |
- |
- |
- |
- |
1件: 97 |
601 |
Multistem low dose |
- |
- |
- |
- |
1件: 97 |
602 |
Myrrh |
Myrrh |
D08948 |
- |
- |
1件: 97 |
603 |
Myrrhinil-intest® |
- |
- |
- |
- |
1件: 97 |
604 |
N.a. |
- |
- |
- |
- |
8件: 3, 6, 8, 13, 46, 97, 240, 256 |
605 |
Naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
606 |
Nand (neoandrographolide) |
- |
- |
- |
- |
1件: 97 |
607 |
Nanocort |
- |
- |
- |
- |
3件: 13, 46, 97 |
608 |
Neomycin |
Neomycin |
D08260 |
- |
- |
3件: 96, 97, 296 |
609 |
Neoral |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
2件: 97, 222 |
610 |
Niclosamide |
Niclosamide |
D00436 |
- |
- |
2件: 46, 97 |
611 |
Nicolon |
- |
- |
- |
- |
1件: 97 |
612 |
Nitazoxanide |
Nitazoxanide |
D02486 |
- |
- |
2件: 96, 97 |
613 |
Nitazoxanide 500mg oral tablet |
Nitazoxanide |
D02486 |
- |
- |
1件: 97 |
614 |
Nivolumab |
Nivolumab |
D10316 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
10件: 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
615 |
Nolpitantium besylate |
- |
- |
- |
- |
1件: 97 |
616 |
Non as of yet |
- |
- |
- |
- |
1件: 97 |
617 |
Normal saline enema |
- |
- |
- |
- |
1件: 97 |
618 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
619 |
Nutrition supplement |
- |
- |
- |
- |
1件: 97 |
620 |
Oats |
- |
- |
- |
- |
1件: 97 |
621 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
622 |
Opc-6535 |
- |
- |
- |
- |
2件: 96, 97 |
623 |
Opc-6535 tablets (drug) |
- |
- |
- |
- |
1件: 97 |
624 |
Opc-6535(tetomilast) |
Tetomilast |
- |
- |
- |
2件: 96, 97 |
625 |
Oprx-106 |
- |
- |
- |
- |
1件: 97 |
626 |
Oprx-106 (plant cells expressing tnfr-fc) 2mg |
- |
- |
- |
- |
1件: 97 |
627 |
Oprx-106 (plant cells expressing tnfr-fc) 8mg |
- |
- |
- |
- |
1件: 97 |
628 |
Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
629 |
Oral okt3 |
- |
- |
- |
- |
1件: 97 |
630 |
Ore1001 |
Ore1001 |
- |
- |
- |
1件: 97 |
631 |
Orencia |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
9件: 46, 50, 51, 53, 65, 84, 96, 97, 271 |
632 |
Originator (legacy) drug |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
633 |
Overencapsulated azathioprine (imuran) 50 mg tablet |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 97 |
634 |
Overencapsulated mesalazine tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
635 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
636 |
Ozanimod |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 96, 97 |
637 |
Ozanimod hydrochloride |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 96, 97 |
638 |
Palmitoleic acid |
Palmitoleic acid |
- |
- |
- |
1件: 97 |
639 |
Pancrelipase |
Pancrelipase |
D05349 |
- |
- |
4件: 96, 97, 298, 299 |
640 |
Parnaparin |
Parnaparin |
D07510 |
1件: SERPINC1 |
1件: Complement and coagulation cascades |
1件: 97 |
641 |
Parnaparin sodium |
Parnaparin |
D07510 |
1件: SERPINC1 |
1件: Complement and coagulation cascades |
1件: 97 |
642 |
Pbf-677 |
- |
- |
- |
- |
1件: 97 |
643 |
Pct (purecell technologies complex) |
- |
- |
- |
- |
1件: 97 |
644 |
Peg-liposomal prednisolone sodium phosphate |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
645 |
Pentasa |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
646 |
Pentasa 2g sachet prolonged release granules (95%) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
647 |
Pentasa 500 mg retardtabletten |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
648 |
Pentasa enema |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
649 |
Pentasa prolonged release granules 2g |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
650 |
Pentasa sachet 1g |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
651 |
Pf 06687234 |
- |
- |
- |
- |
1件: 97 |
652 |
Pf-00547659 sc injection |
- |
- |
- |
- |
2件: 96, 97 |
653 |
Pf-06480605 |
- |
- |
- |
- |
1件: 97 |
654 |
Pf-06651600 |
- |
- |
- |
- |
3件: 46, 96, 97 |
655 |
Pf-06687234 |
- |
- |
- |
- |
1件: 97 |
656 |
Pf-06700841 |
- |
- |
- |
- |
3件: 49, 96, 97 |
657 |
Pfefferminzblätter 1ml/10ml |
- |
- |
- |
- |
1件: 97 |
658 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
659 |
Phosphatidylcholine |
- |
- |
- |
- |
1件: 97 |
660 |
Photodynamic therapy with gliolan |
- |
- |
- |
- |
1件: 97 |
661 |
Picosulfate |
Picosulfuric acid |
- |
- |
- |
2件: 97, 291 |
662 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
663 |
Pn-10884a |
- |
- |
- |
- |
1件: 97 |
664 |
Polaprezinc |
Polaprezinc |
D01611 |
- |
- |
2件: 96, 97 |
665 |
Polyethylene glycol |
Polyethylene glycol |
D03370 |
- |
- |
2件: 96, 97 |
666 |
Polyphenon e® |
- |
- |
- |
- |
1件: 97 |
667 |
Pomegranate |
Pomegranate |
- |
- |
- |
2件: 96, 97 |
668 |
Prd5973697 |
- |
- |
- |
- |
1件: 97 |
669 |
Prednisolon |
- |
- |
- |
- |
4件: 46, 66, 96, 97 |
670 |
Prednisolon jenapharm |
Acetylcysteine |
D00221 |
- |
- |
2件: 96, 97 |
671 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
672 |
Prednisolone sodium metasulphobenzoate |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
673 |
Prednisolone sodium phosphate |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
674 |
Prednisolone tablets b.p. 5mg |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
675 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
676 |
Pro145223 (ro5490261) |
- |
- |
- |
- |
1件: 97 |
677 |
Probiotic mixture |
- |
- |
- |
- |
2件: 96, 97 |
678 |
Probiotics |
- |
- |
- |
- |
4件: 94, 96, 97, 291 |
679 |
Products containing aminosalicylate |
- |
- |
- |
- |
1件: 97 |
680 |
Products containing azathioprine or 6-mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 97 |
681 |
Proline |
Proline |
D00035 |
- |
- |
2件: 94, 97 |
682 |
Propionyl l-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
1件: 97 |
683 |
Propionyl-l-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
1件: 97 |
684 |
Prv-300 |
- |
- |
- |
- |
1件: 97 |
685 |
Ps-qd |
- |
- |
- |
- |
1件: 97 |
686 |
Psyllium |
Plantago seed |
D05525 |
- |
- |
1件: 97 |
687 |
Psyllium husk |
Plantago seed |
D05525 |
- |
- |
1件: 97 |
688 |
Psyllium husk powder |
Plantago seed |
D05525 |
- |
- |
1件: 97 |
689 |
Ptg-100 |
- |
- |
- |
- |
1件: 97 |
690 |
Pur 0110 |
- |
- |
- |
- |
1件: 97 |
691 |
Pur 0110 rectal enema |
- |
- |
- |
- |
1件: 97 |
692 |
Pur 0110 rectal enema 1000 mg |
- |
- |
- |
- |
1件: 97 |
693 |
Pur 0110 rectal enema 250 mg |
- |
- |
- |
- |
1件: 97 |
694 |
Pur 0110 rectal enema 500 mg |
- |
- |
- |
- |
1件: 97 |
695 |
Qbeco ssi |
- |
- |
- |
- |
1件: 97 |
696 |
Raspberry |
Raspberry |
- |
- |
- |
1件: 97 |
697 |
Rdp58 |
- |
- |
- |
- |
1件: 97 |
698 |
Rebamipide |
Rebamipide |
D01121 |
- |
- |
4件: 46, 53, 97, 271 |
699 |
Recombinant factor xiii (rfxiii) |
- |
- |
- |
- |
2件: 97, 288 |
700 |
Rectabul2mg rectal form |
- |
- |
- |
- |
1件: 97 |
701 |
Rectal dialysis |
- |
- |
- |
- |
1件: 97 |
702 |
Rectal tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 97 |
703 |
Regular treatment |
- |
- |
- |
- |
1件: 97 |
704 |
Remicade |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
8件: 46, 49, 56, 84, 85, 96, 97, 271 |
705 |
Remsima |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
706 |
Remsima (infliximab) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
707 |
Remsima - 100 mg polvere per concentrato per soluzione per infusione - uso endovenoso - flanconcino (vetro) - 1 flaconcino |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
708 |
Remsima and inflectra |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
709 |
Retarded release phosphatidylcholine |
- |
- |
- |
- |
1件: 97 |
710 |
Retarded release phosphatidylcholine (rpc) |
- |
- |
- |
- |
1件: 97 |
711 |
Rhil-11 |
- |
- |
- |
- |
1件: 97 |
712 |
Rhumab beta7 |
- |
- |
- |
- |
1件: 97 |
713 |
Rhumab beta7, anti beta7, pro145223 |
- |
- |
- |
- |
1件: 97 |
714 |
Riboflavin |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
8件: 13, 38, 46, 96, 97, 162, 168, 265 |
715 |
Rice |
Rice |
- |
- |
- |
1件: 97 |
716 |
Rifaximin |
Rifaximin |
D02554 |
- |
- |
5件: 6, 96, 97, 99, 296 |
717 |
Risankizumab |
Risankizumab |
D11052 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
4件: 37, 96, 97, 271 |
718 |
Risankizumab (genetical recombination) |
Risankizumab |
D11052 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
1件: 97 |
719 |
Risankizumab iv |
Risankizumab |
D11052 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
2件: 96, 97 |
720 |
Risankizumab sc |
Risankizumab |
D11052 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
2件: 96, 97 |
721 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
722 |
Rivenprost (drug) |
- |
- |
- |
- |
1件: 97 |
723 |
Ro 549-0261/f04 |
- |
- |
- |
- |
1件: 97 |
724 |
Ro7049665 |
- |
- |
- |
- |
1件: 97 |
725 |
Ro7246311 |
- |
- |
- |
- |
1件: 97 |
726 |
Rosiglitazone |
Rosiglitazone |
D00596, D08491 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
5件: 46, 75, 97, 222, 265 |
727 |
Rpc1063 |
- |
- |
- |
- |
3件: 13, 96, 97 |
728 |
Salicylic acid |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
729 |
Saline |
Sodium chloride |
D02056 |
- |
- |
10件: 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
730 |
Salofalk |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
731 |
Salofalk 1000mg granu-stix |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
732 |
Salofalk 4g/60ml klysma |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
733 |
Salofalk granu-stix 500 mg |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
734 |
Salofalk® 1000mg granu-stix® |
- |
- |
- |
- |
1件: 97 |
735 |
Salofalk® 500 mg gastro-resistant tablet |
- |
- |
- |
- |
1件: 97 |
736 |
Salofalk® 500 mg tablets |
- |
- |
- |
- |
1件: 97 |
737 |
Salofalk® 500mg |
- |
- |
- |
- |
1件: 97 |
738 |
Same |
Ademetionine |
D07128 |
- |
- |
15件: 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
739 |
Sandinum |
- |
- |
- |
- |
1件: 97 |
740 |
Sar339658 |
- |
- |
- |
- |
2件: 13, 97 |
741 |
Sb-656933 |
- |
- |
- |
- |
1件: 97 |
742 |
Sb-656933 tablets |
- |
- |
- |
- |
2件: 97, 299 |
743 |
Sb012 |
- |
- |
- |
- |
1件: 97 |
744 |
Sc12267 |
Sc12267 |
- |
- |
- |
3件: 46, 96, 97 |
745 |
Sch 900050 |
- |
- |
- |
- |
1件: 97 |
746 |
Semi-vegetarian diet |
- |
- |
- |
- |
1件: 97 |
747 |
Ser-287 |
- |
- |
- |
- |
1件: 97 |
748 |
Sf257 c59 |
- |
- |
- |
- |
1件: 97 |
749 |
Shingrix |
- |
- |
- |
- |
3件: 46, 96, 97 |
750 |
Shp647 |
- |
- |
- |
- |
2件: 96, 97 |
751 |
Shr0302 |
- |
- |
- |
- |
3件: 46, 96, 97 |
752 |
Simponi |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 97, 271 |
753 |
Simponi (golimumab) |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
754 |
Simponi® (golimumab) |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
755 |
Simulect |
Basiliximab |
D03058 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
2件: 66, 97 |
756 |
Single dose-group a |
- |
- |
- |
- |
1件: 97 |
757 |
Smoking cigarettes |
- |
- |
- |
- |
2件: 96, 97 |
758 |
Smoking of cannabis |
Medical cannabis |
- |
- |
- |
2件: 96, 97 |
759 |
Sodium hyaluronate |
Hyaluronic acid |
D08043 |
- |
- |
1件: 97 |
760 |
Sodium picosulfate/magnesium citrate laxative |
Magnesium citrate |
D03265 |
- |
- |
1件: 97 |
761 |
Solu-medrol |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
762 |
Sotrastaurin |
Sotrastaurin |
D09671 |
4件: PRKCD, PRKCE, PRKCH, PRKCQ |
26件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Aldosterone synthesis and secretion, Apelin signaling pathway, Autophagy - animal, C-type lectin receptor signaling pathway, Chemokine signaling pathway, Estrogen signaling pathway, Fc gamma R-mediated phagocytosis, GnRH signaling pathway, Inflammatory mediator regulation of TRP channels, Insulin resistance, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Shigellosis, Sphingolipid signaling pathway, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 97 |
763 |
Sotrastaurin (inn) acetate |
Sotrastaurin |
D09671 |
4件: PRKCD, PRKCE, PRKCH, PRKCQ |
26件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Aldosterone synthesis and secretion, Apelin signaling pathway, Autophagy - animal, C-type lectin receptor signaling pathway, Chemokine signaling pathway, Estrogen signaling pathway, Fc gamma R-mediated phagocytosis, GnRH signaling pathway, Inflammatory mediator regulation of TRP channels, Insulin resistance, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Shigellosis, Sphingolipid signaling pathway, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 97 |
764 |
Soybean |
Soybean |
- |
- |
- |
1件: 97 |
765 |
Soybean phosphatidylcholine |
Soybean |
- |
- |
- |
1件: 97 |
766 |
Spd476 |
- |
- |
- |
- |
1件: 97 |
767 |
Spd476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
768 |
Spesolimab |
- |
- |
- |
- |
3件: 37, 96, 97 |
769 |
Spesolimab iv infusion |
- |
- |
- |
- |
1件: 97 |
770 |
Spesolimab sc solution for injection |
- |
- |
- |
- |
1件: 97 |
771 |
Sr140333b |
- |
- |
- |
- |
1件: 97 |
772 |
Srt2104 |
Srt2104 |
- |
- |
- |
1件: 97 |
773 |
St 261 |
- |
- |
- |
- |
1件: 97 |
774 |
St-0529 |
- |
- |
- |
- |
1件: 97 |
775 |
St10-021 |
- |
- |
- |
- |
1件: 97 |
776 |
St261 |
- |
- |
- |
- |
1件: 97 |
777 |
Standard 2 hours-infusion |
- |
- |
- |
- |
2件: 96, 97 |
778 |
Standard therapy |
- |
- |
- |
- |
2件: 49, 97 |
779 |
Standardized anthocyanin-rich extract |
- |
- |
- |
- |
1件: 97 |
780 |
Standardized fodmap |
- |
- |
- |
- |
1件: 97 |
781 |
Sterile saline for injection |
- |
- |
- |
- |
1件: 97 |
782 |
Steroids |
- |
- |
- |
- |
7件: 46, 50, 51, 63, 66, 96, 97 |
783 |
Stnm01 |
- |
- |
- |
- |
1件: 97 |
784 |
Stnm01 1.84 mg |
- |
- |
- |
- |
1件: 97 |
785 |
Stw5-ii |
- |
- |
- |
- |
1件: 97 |
786 |
Sucrose |
Sucrose |
D00025 |
- |
- |
3件: 62, 96, 97 |
787 |
Sugar extract |
- |
- |
- |
- |
2件: 96, 97 |
788 |
Sulphsalazine, pentasa, asacol, colazide, depentum |
- |
- |
- |
- |
1件: 97 |
789 |
Suspension containing 7500 embryonated viable trichuris suis ova/15ml |
- |
- |
- |
- |
1件: 97 |
790 |
Suspension de microbiote fécal |
- |
- |
- |
- |
1件: 97 |
791 |
Synergy-1 |
- |
- |
- |
- |
1件: 97 |
792 |
Synergy1 |
- |
- |
- |
- |
1件: 97 |
793 |
Sübetaholzwurzel 1ml/10ml |
- |
- |
- |
- |
1件: 97 |
794 |
Süßholzwurzel 1ml/10ml |
- |
- |
- |
- |
1件: 97 |
795 |
Ta-650 |
- |
- |
- |
- |
4件: 37, 56, 96, 97 |
796 |
Ta-650 (infliximab) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 97, 271 |
797 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
798 |
Tauroursoursodeoxycholic acid, brand name tudcabil |
- |
- |
- |
- |
1件: 97 |
799 |
Td-1473 |
- |
- |
- |
- |
2件: 96, 97 |
800 |
Td-1473 dose a |
- |
- |
- |
- |
1件: 97 |
801 |
Td-1473 dose b |
- |
- |
- |
- |
1件: 97 |
802 |
Td-1473 dose c |
- |
- |
- |
- |
1件: 97 |
803 |
Td-3504 |
- |
- |
- |
- |
1件: 97 |
804 |
Telotristat |
Telotristat |
D09973 |
2件: TPH1, TPH2 |
4件: Folate biosynthesis, Metabolic pathways, Serotonergic synapse, Tryptophan metabolism |
1件: 97 |
805 |
Telotristat etiprate |
Telotristat |
D09973 |
2件: TPH1, TPH2 |
4件: Folate biosynthesis, Metabolic pathways, Serotonergic synapse, Tryptophan metabolism |
1件: 97 |
806 |
Terbinafine |
Terbinafine |
D02219, D02375 |
- |
- |
1件: 97 |
807 |
Tetomilast |
Tetomilast |
- |
- |
- |
2件: 96, 97 |
808 |
Tetracycline |
Tetracycline |
D00201 |
- |
- |
4件: 13, 46, 53, 97 |
809 |
Thalidomide |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
810 |
Thalidomide pharmion |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 85, 96, 97 |
811 |
Threonine |
L-threonine |
D00041 |
- |
- |
3件: 86, 96, 97 |
812 |
Thrx-139060 |
- |
- |
- |
- |
2件: 96, 97 |
813 |
Tj301 300mg |
- |
- |
- |
- |
1件: 97 |
814 |
Tj301 600mg |
- |
- |
- |
- |
1件: 97 |
815 |
Tofacitinib |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
9件: 46, 49, 50, 51, 84, 96, 97, 107, 271 |
816 |
Tofacitinib citrate (clinical trial image) |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
2件: 46, 97 |
817 |
Tofacitinib citrate (proposed commercial formulation – debossed) |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
1件: 97 |
818 |
Top1288 |
Top1288 |
- |
- |
- |
1件: 97 |
819 |
Top1288 rectal solution |
Top1288 |
- |
- |
- |
1件: 97 |
820 |
Tp05 |
- |
- |
- |
- |
1件: 97 |
821 |
Tp05 coating a |
- |
- |
- |
- |
1件: 97 |
822 |
Tp05 coating b |
- |
- |
- |
- |
1件: 97 |
823 |
Tp05 coating d |
- |
- |
- |
- |
1件: 97 |
824 |
Tp05 coating e |
- |
- |
- |
- |
1件: 97 |
825 |
Tp05 coating h |
- |
- |
- |
- |
1件: 97 |
826 |
Traditional treatments |
- |
- |
- |
- |
1件: 97 |
827 |
Tralokinumab |
Tralokinumab |
D09979 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
2件: 85, 97 |
828 |
Trichuris suis eggs |
- |
- |
- |
- |
3件: 13, 96, 97 |
829 |
Trichuris suis ova |
- |
- |
- |
- |
4件: 13, 46, 96, 97 |
830 |
Trichuris suis ova (tso) |
- |
- |
- |
- |
2件: 96, 97 |
831 |
Ucb4940 |
- |
- |
- |
- |
3件: 46, 97, 271 |
832 |
Ucmsc group |
- |
- |
- |
- |
1件: 97 |
833 |
Udca |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
3件: 93, 94, 97 |
834 |
Umbilical cord mesenchymal stem cells |
- |
- |
- |
- |
5件: 13, 46, 57, 97, 113 |
835 |
Upadacitinib |
Upadacitinib |
D10994 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
6件: 41, 46, 49, 96, 97, 271 |
836 |
Upadacitinib (abt-494) |
Upadacitinib |
D10994 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
1件: 97 |
837 |
Updacitinib (abt-494) |
- |
- |
- |
- |
1件: 97 |
838 |
Ur-12746-s |
- |
- |
- |
- |
1件: 97 |
839 |
Ursodeoxycholic acid |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
8件: 6, 67, 84, 93, 94, 95, 96, 97 |
840 |
Ursodiol |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
6件: 8, 20, 93, 97, 234, 299 |
841 |
Ursodiol (ursodeoxycholic acid, udca) |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
1件: 97 |
842 |
Ursofalk |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
4件: 93, 94, 96, 97 |
843 |
Ustekinumab |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
844 |
Ustekinumab iv |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
2件: 49, 97 |
845 |
Ustekinumab sc |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
2件: 49, 97 |
846 |
Uttr1147a |
- |
- |
- |
- |
2件: 96, 97 |
847 |
Uttr1147a, il22-fc, il-22fc |
- |
- |
- |
- |
1件: 97 |
848 |
Uttr1147a/ro7021610 (active) |
- |
- |
- |
- |
1件: 97 |
849 |
Vaccine vivotif + vaccine dukoral |
- |
- |
- |
- |
1件: 97 |
850 |
Vaccine vivotif + vaccine dukoral + oats |
- |
- |
- |
- |
1件: 97 |
851 |
Valganciclovir |
Valganciclovir |
D02495 |
- |
- |
6件: 28, 60, 85, 97, 299, 331 |
852 |
Vaminolac |
- |
- |
- |
- |
1件: 97 |
853 |
Vaminolac, komb. |
- |
- |
- |
- |
1件: 97 |
854 |
Vancomycin |
Vancomycin |
D00212, D00926 |
- |
- |
7件: 46, 70, 94, 96, 97, 296, 299 |
855 |
Vancomycin pre-treat |
Vancomycin |
D00212, D00926 |
- |
- |
1件: 97 |
856 |
Vancomycin pre-treatment |
Vancomycin |
D00212, D00926 |
- |
- |
1件: 97 |
857 |
Vb-201 |
- |
- |
- |
- |
1件: 97 |
858 |
Vb-201 160mg |
- |
- |
- |
- |
1件: 97 |
859 |
Vedolizumab |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
860 |
Vedolizumab 300 mg |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
1件: 97 |
861 |
Vedolizumab injection |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
1件: 97 |
862 |
Vedolizumab intravenous injection |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
863 |
Vedolizumab iv |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
864 |
Vedolizumab iv 300 mg |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
865 |
Vedolizumab sc |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
866 |
Vedolizumab sc 108 mg |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
867 |
Vedolizumab subcutaneous injection |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
868 |
Vidofludimus |
Vidofludimus |
- |
- |
- |
2件: 94, 97 |
869 |
Vidofludimus calcium |
Vidofludimus |
- |
- |
- |
2件: 94, 97 |
870 |
Vigantol oel |
- |
- |
- |
- |
3件: 13, 96, 97 |
871 |
Vigantol oel tm |
- |
- |
- |
- |
2件: 96, 97 |
872 |
Visilizumab |
Visilizumab |
D06314 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
873 |
Visilizumab (hum291 |
Visilizumab |
D06314 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 97 |
874 |
Visilizumab (nuvion) |
Visilizumab |
D06314 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 97 |
875 |
Visilizumab (nuvion® |
Visilizumab |
D06314 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 97 |
876 |
Vitamin b2 |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
1件: 97 |
877 |
Vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
11件: 6, 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 |
878 |
Vitamin e |
Vitamin e |
D02331 |
- |
- |
11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
879 |
Vitamin e 800iu |
Vitamin e |
D02331 |
- |
- |
2件: 96, 97 |
880 |
Vsl#3 |
- |
- |
- |
- |
3件: 96, 97, 291 |
881 |
Vsl#3 (original de simone formulation) |
- |
- |
- |
- |
2件: 96, 97 |
882 |
Vsl#3® |
- |
- |
- |
- |
2件: 96, 97 |
883 |
Water |
Water |
D00001 |
- |
- |
18件: 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |
884 |
Wharton jelly mesenchymal stem cells |
- |
- |
- |
- |
1件: 97 |
885 |
Xeljanz 5 mg film-coated tablets |
- |
- |
- |
- |
1件: 97 |
886 |
Z-206 |
- |
- |
- |
- |
2件: 96, 97 |
887 |
Zoenasa-1:4 |
- |
- |
- |
- |
1件: 97 |